(Q40701437)

22 September 2017

Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus (English)

1 reference

22 September 2017

David L Evers

1

1 reference

22 September 2017

Gloria Komazin

2

1 reference

22 September 2017

Dongjin Shin

3

1 reference

22 September 2017

Debbie D Hwang

4

1 reference

22 September 2017

Leroy B Townsend

5

1 reference

22 September 2017

John C Drach

6

1 reference

22 September 2017

1 October 2002

1 reference

22 September 2017

1 reference

22 September 2017

56

1 reference

22 September 2017

1

1 reference

22 September 2017

61-72

1 reference

Interaction of the herpes simplex virus type 1 packaging protein UL15 with full-length and deleted forms of the UL28 protein

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Foscarnet nephrotoxicity: mechanism, incidence and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

The potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

ATPase activity of the terminase subunit pUL56 of human cytomegalovirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Cidofovir in the treatment of cytomegaloviral disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Differences in DNA packaging genes and sensitivity to benzimidazole ribonucleosides between human cytomegalovirus strains AD169 and Towne.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Potential infectious etiologies of atherosclerosis: a multifactorial perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A three-dimensional model to analyze drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Evaluation of 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic Acid (HEPES) as a Tissue Culture Buffer

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

10.1016/S0166-3542(02)00094-3

Identifiers

DOI

1 reference

22 September 2017

1 reference